Table 1.
Genome-wide Association Study of AD + P (46)
| SNP | Chr | MB | MAF | Closest RefSeq Gene | GWAS p | OR |
|---|---|---|---|---|---|---|
| AD + P vs. AD − P | ||||||
| rs753129 | 4 | 56.4 | .24 | AC110611.1 | 2.85E-07 | .66 |
| rs2969775 | 2 | 47.7 | .37 | AC079250.1 | 2.11E-06 | .68 |
| rs257016 | 5 | 123.2 | .36 | AC008541.1 | 4.06E-06 | .70 |
| rs6509701 | 19 | 58.1 | .30 | ZNF320 | 5.41E-06 | .71 |
| rs16922670a | 9 | 105.1 | .14 | RP11-341A22.2a | 7.22E-06 | 1.63 |
| rs17716202 | 5 | 55.9 | .06 | AC022431.2 | 7.70E-06 | .45 |
| rs3764640a | 19 | 1.2 | .21 | STK11a | 7.88E-06 | .68 |
| rs11252926a | 10 | 0.6 | .36 | DIP2Ca | 8.08E-06 | .72 |
| AD + P vs. Control Subjects | ||||||
| rs6834555 | 4 | 9.7 | .21 | SLC2A9 | 3.06E-07 | 1.39 |
| rs4038131a | 2 | 17.6 | .07 | VSNL1a | 5.90E-07 | .64 |
| rs16970672 | 17 | 73.5 | .29 | AC015804.1 | 1.67E-06 | 1.29 |
| rs9811423a | 3 | 114.3 | .47 | RP11-572M11.4a | 4.18E-06 | 1.28 |
| rs733175a | 4 | 9.7 | .18 | SLC2A9a | 4.97E-06 | 1.36 |
| rs4360367 | 9 | 31.6 | .09 | RP11-402B2.1 | 5.90E-06 | .68 |
| rs4746003 | 10 | 71.2 | .25 | RP11-242G20.2 | 5.95E-06 | 1.29 |
| rs9789748a | 2 | 17.7 | .07 | VSNL1a | 7.39E-06 | 1.50 |
| rs1464108 | 12 | 129.6 | .32 | RIMBP2 | 8.19E-06 | 1.27 |
Results for all loci at p < 1 × 10−5 are shown. For AD + P versus AD − P, 1740 loci had p < 1 × 10−4. For AD + P versus control subjects, 1628 loci had p < 1 × 10−4.
AD + P, Alzheimer’s disease with psychosis; AD − P: Alzheimer’s disease without psychosis; Chr, chromosome; GWAS, genome-wide association study; MAF, minor allele frequency; MB, megabase; OR, odds ratio; RefSeq, reference sequence; SNP, single nucleotide polymorphism.
a
Intragenic SNPs.